Skip to main content

Advertisement

SpringerLink
Log in

Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background

Visceral adiposity index (VAI) is a proposed parameter to evaluate visceral obesity instead of waist circumference (WC) in patients with polycystic ovary syndrome (PCOS). We aimed to evaluate VAI levels in overweight and/or obese, and non-obese PCOS patients and investigate the association between metabolic and inflammatory parameters.

Methods

Seventy-six PCOS patients between 18 and 40, and 38 age- and BMI-matched controls were enrolled into the study. Both PCOS groups and controls were classified into two subgroups according to body mass index (BMI) <25 and ≥25 kg/m2.

Results

In PCOS patients, waist/hip ratio (WHR) (p = 0.023), diastolic blood pressure (DBP) (p = 0.001), insulin (p = 0.011), homeostasis of model assessment (HOMA-IR) (p = 0.006) and uric acid (UA) (p = 0.002) were higher than controls. In overweight and/or obese PCOS group, DBP (p < 0.001), insulin (p = 0.002), HOMA-IR (p = 0.001), triglyceride (p = 0.015) and VAI (p = 0.031) were higher than overweight and/or obese controls. In non-obese PCOS group, WHR (p = 0.016), WC (p = 0.030), DBP (p = 0.010) and UA (p < 0.001) were higher than non-obese controls. Similar VAI levels were found in all PCOS and non-obese PCOS subgroups than peer controls. Overweight and/or obese PCOS group had higher VAI levels than non-obese PCOS group (p < 0.001). VAI levels were positively correlated with WHR, glucose, HOMA-IR, high-sensitive CRP and UA in PCOS group. In controls, VAI levels were positively correlated with WHR, insulin and HOMA-IR.

Conclusion

We found that VAI levels were higher in overweight and/or obese PCOS patients compared to peer controls and non-obese PCOS patients, and associated with some metabolic and inflammatory parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ, Yildiz BO (2016) Polycystic ovary syndrome. Nat Rev Dis Prim 2:16057. doi:10.1038/nrdp.2016.57

    Article  PubMed  Google Scholar 

  2. Orio F, Muscogiuri G, Nese C, Palomba S, Savastano S, Tafuri D, Colarieti G, La Sala G, Colao A, Yildiz BO (2016) Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. doi:10.1016/j.ejogrb.2016.08.026

    PubMed  Google Scholar 

  3. Amato MC, Vesco R, Vigneri E, Ciresi A, Giordano C (2015) Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance. J Endocrinol Invest 38(12):1319–1326. doi:10.1007/s40618-015-0372-x

    Article  CAS  PubMed  Google Scholar 

  4. Kucukaydin Z, Duran C, Basaran M, Camlica F, Erdem SS, Basaran A, Kutlu O, Burnik FS, Elmas H, Gonen MS (2016) Plasma total oxidant and antioxidant status after oral glucose tolerance and mixed meal tests in patients with polycystic ovary syndrome. J Endocrinol Invest 39(10):1139–1148. doi:10.1007/s40618-016-0498-5

    Article  CAS  PubMed  Google Scholar 

  5. Polak K, Czyzyk A, Simoncini T, Meczekalski B (2016) New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest. doi:10.1007/s40618-016-0523-8

    PubMed  PubMed Central  Google Scholar 

  6. Lim SS, Davies MJ, Norman RJ, Moran LJ (2012) Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 18(6):618–637. doi:10.1093/humupd/dms030

    Article  CAS  PubMed  Google Scholar 

  7. Borruel S, Fernandez-Duran E, Alpanes M, Marti D, Alvarez-Blasco F, Luque-Ramirez M, Escobar-Morreale HF (2013) Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 98(3):1254–1263. doi:10.1210/jc.2012-3698

    Article  CAS  PubMed  Google Scholar 

  8. Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, O’Donnell CJ, Fox CS, Hoffmann U (2009) Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J 30(7):850–856. doi:10.1093/eurheartj/ehn573

    Article  PubMed  PubMed Central  Google Scholar 

  9. Lim SS, Norman RJ, Davies MJ, Moran LJ (2013) The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev Off J Int Assoc Stud Obes 14(2):95–109. doi:10.1111/j.1467-789X.2012.01053.x

    Article  CAS  Google Scholar 

  10. Glintborg D, Petersen MH, Ravn P, Hermann AP, Andersen M (2016) Comparison of regional fat mass measurement by whole body DXA-scans and anthropometric measures to predict insulin resistance in women with polycystic ovary syndrome and controls. Acta Obstet Gynecol Scand. doi:10.1111/aogs.12964

    PubMed  Google Scholar 

  11. Amato MC, Guarnotta V, Giordano C (2013) Body composition assessment for the definition of cardiometabolic risk. J Endocrinol Invest 36(7):537–543. doi:10.3275/8943

    CAS  PubMed  Google Scholar 

  12. Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y (2000) Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 72(3):694–701

    CAS  PubMed  Google Scholar 

  13. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J (2005) The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 12(6):295–300

    Article  CAS  PubMed  Google Scholar 

  14. Goodpaster BH, Krishnaswami S, Harris TB, Katsiaras A, Kritchevsky SB, Simonsick EM, Nevitt M, Holvoet P, Newman AB (2005) Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med 165(7):777–783. doi:10.1001/archinte.165.7.777

    Article  PubMed  Google Scholar 

  15. Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabetes Med J Br Diabetes Assoc 23(5):469–480. doi:10.1111/j.1464-5491.2006.01858.x

    Article  CAS  Google Scholar 

  16. Rossner S, Bo WJ, Hiltbrandt E, Hinson W, Karstaedt N, Santago P, Sobol WT, Crouse JR (1990) Adipose tissue determinations in cadavers—a comparison between cross-sectional planimetry and computed tomography. Int J Obes 14(10):893–902

    CAS  PubMed  Google Scholar 

  17. Sasai H, Brychta RJ, Wood RP, Rothney MP, Zhao X, Skarulis MC, Chen KY (2015) Does visceral fat estimated by dual-energy X-ray absorptiometry independently predict cardiometabolic risks in adults? J Diabetes Sci Technol 9(4):917–924. doi:10.1177/1932296815577424

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Amato MC, Giordano C (2014) Visceral adiposity index: an indicator of adipose tissue dysfunction. Int J Endocrinol 2014:730827. doi:10.1155/2014/730827

    Article  PubMed  PubMed Central  Google Scholar 

  19. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, AlkaMeSy Study G (2010) Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33(4):920–922. doi:10.2337/dc09-1825

    Article  PubMed  PubMed Central  Google Scholar 

  20. Amato MC, Guarnotta V, Forti D, Donatelli M, Dolcimascolo S, Giordano C (2013) Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment. Hum Reprod 28(7):1919–1928. doi:10.1093/humrep/det105

    Article  CAS  PubMed  Google Scholar 

  21. Liu PJ, Ma F, Lou HP, Chen Y (2016) Visceral adiposity index is associated with pre-diabetes and type 2 diabetes mellitus in chinese adults aged 20–50. Ann Nutr Metab 68(4):235–243. doi:10.1159/000446121

    Article  CAS  PubMed  Google Scholar 

  22. Vogel P, Stein A, Marcadenti A (2016) Visceral adiposity index and prognosis among patients with ischemic heart failure. Sao Paulo Med J Rev Paul Med 134(3):211–218. doi:10.1590/1516-3180.2015.01452111

    Article  Google Scholar 

  23. Jiang J, Deng S, Chen Y, Liang S, Ma N, Xu Y, Chen X, Cao X, Song C, Nie W, Wang K (2016) Comparison of visceral and body fat indices and anthropometric measures in relation to untreated hypertension by age and gender among Chinese. Int J Cardiol 219:204–211. doi:10.1016/j.ijcard.2016.06.032

    Article  PubMed  Google Scholar 

  24. Techatraisak K, Wongmeerit K, Dangrat C, Wongwananuruk T, Indhavivadhana S (2016) Measures of body adiposity and visceral adiposity index as predictors of metabolic syndrome among Thai women with PCOS. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 32(4):276–280. doi:10.3109/09513590.2015.1112785

    Article  CAS  Google Scholar 

  25. Janghorbani M, Amini M (2016) The visceral adiposity index in comparison with easily measurable anthropometric markers did not improve prediction of diabetes. Can J Diabetes. doi:10.1016/j.jcjd.2016.02.008

    PubMed  Google Scholar 

  26. Borruel S, Molto JF, Alpanes M, Fernandez-Duran E, Alvarez-Blasco F, Luque-Ramirez M, Escobar-Morreale HF (2014) Surrogate markers of visceral adiposity in young adults: waist circumference and body mass index are more accurate than waist hip ratio, model of adipose distribution and visceral adiposity index. PLoS ONE 9(12):e114112. doi:10.1371/journal.pone.0114112

    Article  PubMed  PubMed Central  Google Scholar 

  27. Un B, Dolapcioglu KS, Guler Okyay A, Sahin H, Beyazit A (2016) Evaluation of hs-CRP and visseral adiposity index in patients with policystic ovary syndrome by clinical and laboratory findings. Eur J Obstet Gynecol Reprod Biol 204:16–20. doi:10.1016/j.ejogrb.2016.06.022

    Article  CAS  PubMed  Google Scholar 

  28. Rotterdam EA-SPCWG (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81(1):19–25

    Article  Google Scholar 

  29. Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan R, Bush A, Richmond W, Johnston DG, Franks S (1996) Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol 44(3):277–284

    Article  CAS  Google Scholar 

  30. Hoffman LK, Ehrmann DA (2008) Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 4(4):215–222. doi:10.1038/ncpendmet0755

    Article  CAS  PubMed  Google Scholar 

  31. Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, Lehnert H (2012) Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 33(5):812–841. doi:10.1210/er.2012-1003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Wild RA, Rizzo M, Clifton S, Carmina E (2011) Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 95(3):1073–1079. doi:10.1016/j.fertnstert.2010.12.027

    Article  CAS  PubMed  Google Scholar 

  33. Joharatnam J, Barber TM, Webber L, Conway GS, McCarthy MI, Franks S (2011) Determinants of dyslipidaemia in probands with polycystic ovary syndrome and their sisters. Clin Endocrinol 74(6):714–719. doi:10.1111/j.1365-2265.2011.03983.x

    Article  Google Scholar 

  34. Manneras-Holm L, Leonhardt H, Kullberg J, Jennische E, Oden A, Holm G, Hellstrom M, Lonn L, Olivecrona G, Stener-Victorin E, Lonn M (2011) Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab 96(2):E304–E311. doi:10.1210/jc.2010-1290

    Article  CAS  PubMed  Google Scholar 

  35. Maddaloni E, Cavallari I, De Pascalis M, Keenan H, Park K, Manfrini S, Buzzetti R, Patti G, Di Sciascio G, Pozzilli P (2016) Relation of body circumferences to cardiometabolic disease in overweight-obese subjects. Am J Cardiol. doi:10.1016/j.amjcard.2016.06.044

    PubMed  Google Scholar 

  36. Oh JY, Sung YA, Lee HJ (2013) The visceral adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome. Obesity 21(8):1690–1694. doi:10.1002/oby.20096

    Article  CAS  PubMed  Google Scholar 

  37. Bil E, Dilbaz B, Cirik DA, Ozelci R, Ozkaya E, Dilbaz S (2016) Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype. J Obstet Gynaecol Res 42(7):837–843. doi:10.1111/jog.12985

    Article  CAS  PubMed  Google Scholar 

  38. Ramezani Tehrani F, Minooee S, Azizi F (2014) Comparison of various adiposity indexes in women with polycystic ovary syndrome and normo-ovulatory non-hirsute women: a population-based study. Eur J Endocrinol Eur Fed Endocr Soc 171(2):199–207. doi:10.1530/EJE-14-0094

    Article  Google Scholar 

  39. Androulakis II, Kandaraki E, Christakou C, Karachalios A, Marinakis E, Paterakis T, Diamanti-Kandarakis E (2014) Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome. Clin Endocrinol 81(3):426–431. doi:10.1111/cen.12447

    Article  CAS  Google Scholar 

  40. Amato MC, Verghi M, Galluzzo A, Giordano C (2011) The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Hum Reprod 26(6):1486–1494. doi:10.1093/humrep/der088

    Article  PubMed  Google Scholar 

  41. Amato MC, Giordano C, Pitrone M, Galluzzo A (2011) Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis 10:183. doi:10.1186/1476-511X-10-183

    Article  PubMed  PubMed Central  Google Scholar 

  42. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SS (1996) Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 81(8):2854–2864. doi:10.1210/jcem.81.8.8768842

    CAS  PubMed  Google Scholar 

  43. Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38(9):1165–1174

    Article  CAS  PubMed  Google Scholar 

  44. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS (2000) Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 15(6):1266–1274

    Article  CAS  PubMed  Google Scholar 

  45. Holte J, Bergh T, Berne C, Berglund L, Lithell H (1994) Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 78(5):1052–1058. doi:10.1210/jcem.78.5.8175959

    CAS  PubMed  Google Scholar 

  46. Ovesen P, Moller J, Ingerslev HJ, Jorgensen JO, Mengel A, Schmitz O, Alberti KG, Moller N (1993) Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. J Clin Endocrinol Metab 77(6):1636–1640. doi:10.1210/jcem.77.6.8263152

    CAS  PubMed  Google Scholar 

  47. Layegh P, Mousavi Z, Farrokh Tehrani D, Parizadeh SM, Khajedaluee M (2016) Insulin resistance and endocrine-metabolic abnormalities in polycystic ovarian syndrome: comparison between obese and non-obese PCOS patients. Int J Reprod Biomed 14(4):263–270

    Google Scholar 

  48. Amato MC, Magistro A, Gambino G, Vesco R, Giordano C (2015) Visceral adiposity index and DHEAS are useful markers of diabetes risk in women with polycystic ovary syndrome. Eur J Endocrinol Eur Fed Endocr Soc 172(1):79–88. doi:10.1530/EJE-14-0600

    Article  CAS  Google Scholar 

  49. Elci E, Kaya C, Cim N, Yildizhan R, Elci GG (2016) Evaluation of cardiac risk marker levels in obese and non-obese patients with polycystic ovaries. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. doi:10.1080/09513590.2016.1203893

    Google Scholar 

  50. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B (2005) Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 90(11):6014–6021. doi:10.1210/jc.2005-1002

    Article  CAS  PubMed  Google Scholar 

  51. Karaer A, Cavkaytar S, Mert I, Buyukkagnici U, Batioglu S (2010) Cardiovascular risk factors in polycystic ovary syndrome. J Obstet Gynaecol J Inst Obstet Gynaecol 30(4):387–392. doi:10.3109/01443611003763408

    Article  CAS  Google Scholar 

  52. Ganie MA, Hassan S, Nisar S, Shamas N, Rashid A, Ahmed I, Douhat S, Mudassar S, Jan VM, Rashid F (2014) High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 30(11):781–784. doi:10.3109/09513590.2014.924099

    Article  CAS  Google Scholar 

  53. Jeong K, Park SY, Jeon JH, Lee SR, Chung HW (2016) Predictive markers for abnormal glucose intolerance in women with polycystic ovary syndrome. Miner Med 107(4):185–193

    Google Scholar 

  54. Amato MC, Pizzolanti G, Torregrossa V, Misiano G, Milano S, Giordano C (2014) Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS ONE 9(3):e91969. doi:10.1371/journal.pone.0091969

    Article  PubMed  PubMed Central  Google Scholar 

  55. Walch K, Grimm C, Nagele F, Huber J, Wolfler M, Vytiska-Binstorfer E, Unfried G, Hefler L (2006) Impaired glucose tolerance is associated with changes in clinical and biochemical parameters in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 85(7):869–873. doi:10.1080/00016340500342938

    Article  CAS  PubMed  Google Scholar 

  56. Anttila L, Rouru J, Penttila T, Irjala K (1996) Normal serum uric acid concentrations in women with polycystic ovary syndrome. Hum Reprod 11(11):2405–2407

    Article  CAS  PubMed  Google Scholar 

  57. Luque-Ramirez M, Alvarez-Blasco F, Uriol Rivera MG, Escobar-Morreale HF (2008) Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Hum Reprod 23(7):1594–1601. doi:10.1093/humrep/den095

    Article  CAS  PubMed  Google Scholar 

  58. Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 283(18):2404–2410

    Article  CAS  PubMed  Google Scholar 

  59. Mantzoros CS, Georgiadis EI, Young R, Evagelopoulou C, Khoury S, Katsilambros N, Sowers JR (1995) Relative androgenicity, blood pressure levels, and cardiovascular risk factors in young healthy women. Am J Hypertens 8(6):606–614. doi:10.1016/0895-7061(95)00051-P

    Article  CAS  PubMed  Google Scholar 

  60. Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E (1995) Effect of insulin on uric acid excretion in humans. Am J Physiol 268(1 Pt 1):E1–E5

    CAS  PubMed  Google Scholar 

Download references

Funding

This study was funded by the research fund of Konya Training and Research Hospital.

Author information

Authors and Affiliations

  1. Division of Endocrinology and Internal Medicine, Konya Health Application and Research Center, University of Health Sciences, Meram Yeniyol, Meram, 42100, Konya, Turkey

    C. Duran

  2. Department of Internal Medicine, Konya Health Application and Research Center, University of Health Sciences, Meram Yeniyol, Meram, 42100, Konya, Turkey

    U. Durmus & S. Ecirli

Authors
  1. U. Durmus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Duran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Ecirli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Duran.

Ethics declarations

Conflicts of interest

Authors declare no conflicts of interest.

Research involving human participants and/or animals

All procedures in the study involving human participants were performed in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Durmus, U., Duran, C. & Ecirli, S. Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters. J Endocrinol Invest 40, 487–497 (2017). https://doi.org/10.1007/s40618-016-0582-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-016-0582-x

Keywords

Search

Navigation